摘要
目的观察卡维地洛对2型糖尿病并发冠心病心力衰竭患者的心功能及血脂、血糖、胰岛素抵抗的影响。方法2型糖尿病并发冠心病心力衰竭患者105例,根据常规治疗基础上加用卡维地洛与否分为治疗组和对照组。治疗12个月,观察卡维地洛对心功能及血脂、血糖、胰岛素抵抗的指标变化。结果①卡维地洛用量平均(12±4)mg/d。②对心功能及心室重构的影响:与对照组相比,治疗组12个月左室射血分数较对照组显著升高[(50±4)%与(45±6)%,P<0.01],左室收缩末容积下降[(166±41)ml与(184±38)ml,P<0.01]。NYHA分级也明显改善。③治疗12个月后治疗组与对照组血脂及空腹血糖、胰岛素、胰岛素抵抗指数均无明显变化。结论卡维地洛能明显改善2型糖尿病并发冠心病心力衰竭患者的心功能和心室重构,而对其血脂及空腹血糖、胰岛素、胰岛素抵抗指数无明显影响,可以安全应用于2型糖尿病并发冠心病心力衰竭患者。
AIM To study the effect of Carvedilol in patients with heart failure due to type 2 diabetes mellitus and coronary heart disease. METHODS One hundred and five patients were divided into treatment group （with Carvedilol） and control group （without Carvedilol） and the changes of Carvedilol on left ventricular function, blood-lipoids, concentration of fast plasma glucose（FPG） , fast insulins （FNS） and HOMA-IR were observed. RESULTS The average dose of Carvedilol was （12 ±4）mg/d and the patients in treatment group had better results than those in control group according to NYHA function class after 12 months＇ treatment. During follow-up, the LVEF at 12 months increased by （50 ±4）% in the Carvedilol group compared with the control group （45 ± 6）% （P 〈 0.01 ） and LVESV reduced by （ 166± 41 ） ml in the Carvedilol group compared with that in the control group （ 184 ± 38 ） ml （ P 〈 0.01 ）. There was no significant change in blood-lipoids, concentration of FPG, FNS and HOMA-IR after 12 months＇ treatment. CONCLUSION Carvedilol can improve the left ventricular function and re- modeling in patients with heart failure due to type 2 diabetes mellitus and coronary heart disease and has no influence on blood-lipoids, concentration of FPG FNS and HOMA-IR.
出处
《心脏杂志》
CAS
2007年第1期70-73,共4页
Chinese Heart Journal
关键词
卡维地洛
心力衰竭
糖尿病
冠状动脉疾病
血脂
carvedilol
heart failure
diabetes mellitus
coronary disease
blood-lipoids
